CEO SUMMARY: One 15-member pathology group said adopting digital pathology will give it more competitive advantage. Advanced Pathology Associates (APA) in suburban Maryland, was one of four sites that participated in the clinical study of the Philips IntelliSite Pathology Solution application for FDA clearance to use the system for primary diagnosis. The experience was of
Tag: digital pathology systems
CEO SUMMARY: Proponents of digital pathology systems and whole slide imaging achieved a milestone on April 12 when the FDA cleared the Philips digital pathology system for sale in the United States. Now pathologists can use the system to perform primary diagnoses and get paid for those professional services. It is expected that this regulatory
IN RECENT WEEKS, pathology laboratory clients of the Omnyx digital pathology system learned that the joint venture is ending. Company officials tell these customers that their digital pathology systems will continue to receive service.
Omnyx was formed in 2008 as a joint venture between GE Healthcare and the University of Pittsburgh Medical Center (UPMC). Its goal
CEO SUMMARY: For years, the adoption of digital pathology has lagged behind the predictions of its advocates. That has encouraged one digital pathology company—Inspirata, Inc., of Tampa—to come up with a different business strategy designed to help anatomic pathology labs address the barriers and capital costs involved with establishing a digital pathology system. The Ohio
IN THE 2000S, DIGITAL PATHOLOGY WAS THE HOT NEW TECHNOLOGY that held great potential to transform anatomic pathology in myriad ways, not the least of which was an essential tool to streamline pathologist workflow while supporting greater diagnostic precision.
Yet today, approximately 10 years later, those high hopes for the digital pathology market have not come
CEO SUMMARY: There’s a new competitor in the digital pathology marketplace with ambitious plans to deliver a fully-integrated pathologist workflow solution. Inspirata, Inc., of Tampa, Florida, made its debut in March at an international pathology conference. In this exclusive interview, Inspirata Chairman and CEO Satish K. Sanan explains his company’s strategic vision for digital pathology, along with the details of how Inspirata intends to overcome digital pathology’s return-on-investment challenge.
CEO SUMMARY: Are clinical labs and pathology groups ready for the end of fee-for-service reimbursement? That’s just one important question that will be answered at the upcoming Executive War College on Lab and Pathology Management that will take place in New Orleans on April 29-30. The American healthcare system is undergoing unprecedented transformation and sessions
There is progress on the integration of digital pathology systems and proprietary algorithms designed to help pathologists make diagnoses. This month, Visiopharm and Omnyx LLC, announced a joint venture. On its own, in Europe last year, Visiopharm earned a CE mark for its “in vitro diagnostic (IVD) software module for the breast cancer marker HER2.”
Big news last week was the unanimous decision by the Supreme Court that natural genes cannot be patented. The case was brought against Myriad Genetics, Inc., by the American Civil Liberties Union, the Association for Molecular Pathology, and several other plaintiffs. The decision invalidated some of the patents held by Myriad for the BRCA 1
Definiens AG, one of the major players in the fast-growing market for digital pathology, raised $12.8 million in additional capital funding. The company, based in Munich, Germany, manufacturers systems for digital image analysis. Definiens stated that the new funds will be used for “commercial expansion of its current business and to develop and commercialize innovative